Press release as PDF

Nomination Committee proposes new Board of Directors ahead of 2013 AGM

Stockholm, Sweden — Medivir AB (OMX: MVIR) today published the proposal for the new Board of Directors submitted by the Nomination Committee ahead of the 2013 Annual General Meeting.

The 2012-2013 Nomination Committee comprises representatives of the three largest shareholders at the end of Q3 2012 who accepted the invitation to become members of the Nomination Committee, and the Chairman of the Board. The composition of the 2012-2013 Nomination Committee was as follows:

Anders Algotson, Chairman of the Nomination Committee, representing AFA Försäkring
Annelie Enquist, representing Skandia Fonder
Göran Pettersson, Chairman of the Board of Medivir AB
Bo Öberg, representing the class A shareholders

The Nomination Committee now proposes, ahead of the 2013 Annual General Meeting, that a new Board of Directors be appointed by means of the re-election of the six existing Members of the Board, namely Björn C. Andersson, Anna Malm Bernsten, Rolf A. Classon, Anders Hallberg, Ingemar Kihlström, and Göran Pettersson, and the new election of two Members, namely Birgitta Stymne Göransson and Bo Öberg. The Nomination Committee also proposes the re-election of the Chairman of the Board, Göran Pettersson.

Birgitta Stymne Göransson, born 1957, is the CEO of Memira AB. Birgitta is a graduate engineer who majored in biotechnology at the Royal Institute of Technology in Stockholm and who also holds a Master of Business Administration degree from Harvard Business School. Birgitta has many years’ experience of senior executive positions in trade and industry and has worked in Sweden and the rest of the Nordic region, and in the USA. She is currently a member of the board of directors at Elekta AB, Rhenman & Partners Asset Management AB and the Stockholm Chamber of Commerce.

Professor Bo Öberg, born 1939, is an adjunct professor in virology at Karolinska Institutet and has 180 publications in virology and antiviral research. Bo is a founder of Medivir and represents the class A shareholders. He has been employed by Medivir since 1988 and has previously been a member of Medivir’s board of directors during 1988 – 2009. Bo is currently a board member at Beactica AB.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292.

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on infectious diseases.

Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor in late phase III clinical development for hepatitis C that is being developed in collaboration with Janssen R&D Ireland.

Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website: www.medivir.com

Page updated 15 maj 2017